NCT05476224 (COVI-LIPI-D) is a clinical trial of Blood sample of 30 ml in SARS-CoV2 Infection, sponsored by Centre Hospitalier Universitaire Dijon.

Who is sponsoring NCT05476224?

NCT05476224 is sponsored by Centre Hospitalier Universitaire Dijon.

What drugs are being tested in NCT05476224?

Interventions in NCT05476224: Blood sample of 30 ml.

What condition does NCT05476224 study?

NCT05476224 studies SARS-CoV2 Infection.

Is NCT05476224 still recruiting?

NCT05476224 is currently completed. Last updated 2 October 2023.

Last reviewed 2023-10-02 · How we verify

NCT05476224: COVI-LIPI-D

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Qualitative and Functional Investigation of Lipids in Patients With SARS-CoV2 Infection - In Search of Atherogenic Sequelae

Completed Last updated 2 October 2023

What this trial tests

trial testing Blood sample of 30 ml in SARS-CoV2 Infection in 228 participants. Completed in 12 April 2023.

Timeline

14 June 2022

Primary endpoint
12 April 2023

12 April 2023

Quick facts

Lead sponsor	Centre Hospitalier Universitaire Dijon
Status	Completed
Study type	OBSERVATIONAL
Enrollment	228
Start date	14 June 2022
Primary completion	12 April 2023
Estimated completion	12 April 2023
Sites	1 location across France

Drugs / interventions tested

Blood sample of 30 ml — full drug profile →

Conditions studied

SARS-CoV2 Infection — all drugs for SARS-CoV2 Infection →

Sponsor

Centre Hospitalier Universitaire Dijon

Who can join

18 and older, any sex, with SARS-CoV2 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Currently, the world is facing a SARS-CoV2 coronavirus epidemic, which is responsible for COVID-19. In France, this virus has already infected several million people and is responsible for the death of more than 127,000. Infection is associated with a higher number of cardiovascular events (myocardial infarction, stroke, cardiac arrhythmia, thrombosis ...) in the short and medium term after infection. The long-term complications of this infection are not yet known and are the subject of research in France and in the world. In order to investigate the possible long term sequelae of this virus infection, this research aims to evaluate the potential cholesterol abnormalities caused by COVID-19, which could play a significant role in the increase of cardiovascular risk in affected patients. A total of 180 analysable participants will be recruited in this study. They will be divided into four groups of participants that will be compared to one another: * 30 participants who were infected with SARS-CoV2 with no or few signs and did not require hospitalization. * 30 participants who were infected with SARS-CoV2 and whose severity of illness required hospitalization in a COVID unit * 30 participants who were infected with SARS-CoV2 and required intensive care hospitalization due to severity of illness. * 90 participants who were not infected with SARS-CoV2. For each participant, the study will last approximately 1 hour, the time to fill out the consent forms, to answer a few questions about their current medical history and finally to take a blood sample for lipid measurements.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for SARS-CoV2 Infection

Currently open trials in the same condition.

NCT05852873 — PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway · Phase 3 · active not recruiting
NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
NCT04830852 — Pediatric COVID Outcomes Study (PECOS) · active not recruiting
NCT04844242 — MISC COVID-19 Study in Pediatric Population · recruiting

Other Centre Hospitalier Universitaire Dijon trials

Trials by the same sponsor.

NCT06608004 — Influence of Olfacto-gustatory Sensoriality on the Nutritional Status of Patients With Amyotrophic Lateral Sclerosis · recruiting
NCT07432789 — Metrological Properties of a Digital Motion Analysis Research Application for Assessing the Motor Abilities and Performa · NA · recruiting
NCT06776848 — A Pilot, Multicentre, Controlled, Open-label Study Evaluating 24 Months of Lithium Carbonate Treatment in Patients With · Phase 1, PHASE2 · recruiting
NCT06347302 — Study of Vitreoretinal Molecular Changes During Rhegmatogenous Retinal Detachment · NA · completed
NCT06252415 — Evaluation of Rapid First-line Genome Sequencing for Prenatal Diagnosis of Congenital Malformations in Comparison With C · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05476224 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire Dijon
Last refreshed: 2 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05476224.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing